Boston Scientific is trading 4.90% down at $42.85 after its October 28, 2026, earnings release lowered its full-year outlook. - Third-quarter sales were $5.138 billion and adjusted EPS was $0.73. - It now expects full-year adjusted EPS of $3.16–$3.18 and fourth-quarter sales to decline 1%–3%. - Management cited the August cybersecurity incident’s impact on operations and financial results; coverage described a negative premarket reaction to the lowered outlook.